Indian pharma set to see further consolidation
The Indian pharmaceutical sector is set to see both inbound and domestic consolidation, although high valuations and regulatory uncertainty dampen M&A activity in the short-term. Local companies will also seek offshore purchases.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts